Breaking News Instant updates and real-time market news.

JD

JD.com

$29.05

-0.27 (-0.92%)

, NIO

NIO Inc.

$8.01

-2.11 (-20.85%)

07:35
03/07/19
03/07
07:35
03/07/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Wednesday in JD.com (JD), NIO Inc (NIO), CVS Health (CVS), Qualcomm (QCOM), Roku (ROKU), Aurora Cannabis (ACB), Caterpillar (CAT), Target (TGT), VMware (VMW), and Uxin Ltd (UXIN).

JD

JD.com

$29.05

-0.27 (-0.92%)

NIO

NIO Inc.

$8.01

-2.11 (-20.85%)

CVS

CVS Health

$54.00

-0.98 (-1.78%)

QCOM

Qualcomm

$54.80

1.48 (2.78%)

ROKU

Roku

$71.91

3.11 (4.52%)

ACB

Aurora Cannabis

$7.87

-0.22 (-2.72%)

CAT

Caterpillar

$134.80

-2.36 (-1.72%)

TGT

Target

$76.89

0.89 (1.17%)

VMW

VMware

$170.11

-2.58 (-1.49%)

UXIN

Uxin

$5.40

0.25 (4.85%)

  • 14

    Mar

  • 19

    Mar

  • 20

    Mar

  • 17

    Apr

  • 09

    Jul

JD JD.com
$29.05

-0.27 (-0.92%)

03/01/19
BNCH
03/01/19
NO CHANGE
Target $34
BNCH
Buy
JD.com price target raised to $34 after 'solid quarter' at Benchmark
Benchmark analyst Fawne Jiang said JD.com reported "solid" Q4 results, with upside driven by healthy core e-commerce growth as well as improving margin trends. Despite ongoing macro concerns, Q1 revenue guidance and full year margin guidance were above expectations, said Jiang, who raised her price target on JD.com shares to $34 from $31 and keeps a Buy rating on the stock.
01/31/19
UBSW
01/31/19
DOWNGRADE
UBSW
Neutral
JD.com downgraded to Neutral from Buy at UBS
01/14/19
BERN
01/14/19
INITIATION
Target $16
BERN
Market Perform
JD.com assumed with a Market Perform at Bernstein
Bernstein analyst David Dai assumed coverage on JD with a Market Perform and $16 price target.
03/01/19
LYON
03/01/19
UPGRADE
Target $31
LYON
Outperform
JD.com upgraded to Outperform from Underperform at CLSA
CLSA analyst Elinor Leung upgraded JD.com to Outperform from Underperform after the company reported "weak," but better than expected, top-line growth in Q4 along with a margin beat on better cost control. 2019 margins are expected to improve further, noted Leung, who raised the firm's price target on JD.com shares to $31 from $24.
NIO NIO Inc.
$8.01

-2.11 (-20.85%)

01/15/19
EGHT
01/15/19
INITIATION
EGHT
Sell
86 Research starts NIO Inc. with a Sell rating, $4.70 price target
86 Research analyst Robert Cowell initiated coverage of NIO Inc. (NIO) with a Sell rating and $4.70 price target, stating that the company offers "attractive" fully electric SUVs at "attractive" prices in China, but is "losing large sums of money by doing so." He has concerns that NIO's operations are not efficient enough and said it does not have the same potential to revolutionize EV manufacturing as Tesla (TSLA) does. Additionally, the company's price advantage for its SUVs over Tesla cars is reliant on government subsidies, noted Cowell.
03/06/19
BOFA
03/06/19
DOWNGRADE
Target $6.8
BOFA
Underperform
NIO Inc. downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Ming Hsun Lee downgraded NIO Inc. (NIO) to Underperform from Neutral and cut its price target to $6.80 from $8. Lee expects ES8's sales volume growth to be lower than his previous expectations and for increased incentives to reduce profitability following Tesla's (TLSA) recent price cuts in China and the upcoming cut in EV purchase subsidy in 2019. The analyst views NIO's valuation as "rich" and lowered his shipment forecasts below guidance for 2019/20.
03/07/19
GSCO
03/07/19
INITIATION
Target $10.7
GSCO
Buy
NIO Inc. reinstated with a Buy at Goldman Sachs
Goldman Sachs analyst Fei Fang reinstated NIO Inc with a Buy and $10.70 price target. Fang said shares have corrected following Q4 results and sees key drivers that include a light business model, successful premium segment branding, economically constrained competitors, and a large volume opportunity for the ES6.
01/15/19
EGHT
01/15/19
INITIATION
Target $4.7
EGHT
Sell
NIO Inc. initiated with a Sell at 86 Research
86 Research initiated NIO Inc with a Sell adn $4.70 price target.
CVS CVS Health
$54.00

-0.98 (-1.78%)

02/25/19
ARGS
02/25/19
NO CHANGE
Target $80
ARGS
Buy
CVS Health price target lowered to $80 from $100 at Argus
Argus analyst Chris Graja lowered his price target on CVS Health to $80 after its Q4 results and lower than expected outlook for 2019 earnings, forecasting the market environment for the company to remain "difficult" with a lower than previously modeled buyback activity. The analyst is keeping his Buy rating on CVS Health longer term however, with a positive view on its Aetna acquisition being the "logical continuation of management's plan to provide innovative ways to help both healthcare payers and individual patients."
03/06/19
SBSH
03/06/19
NO CHANGE
Target $68
SBSH
Buy
CVS Health price target lowered to $68 from $94 at Citi
Citi analyst Ralph Giacobbe lowered his price target for CVS Health to $68 from $94 but keeps a Buy rating on the shares. The analyst says that while headwinds within the company's retail are significant, he's most surprised with the sizable drop implied within the healthcare benefits segment. However, he sees "a bridge" that gives credence to mid-single digit underlying growth. While admitting it is difficult to gain visibility on 2020, Giacobbe sees a "reasonable path" to $7.20 in earnings per share for 2020.
03/04/19
BARD
03/04/19
NO CHANGE
BARD
Baird investigation finds Ohio, like many buyers, paying too much for drugs
In a research note titled "Major Confusion: Does This Pass Your Sniff Test?," Baird analyst Eric Coldwell details the interplay between Cardinal Health's (CAH) generic marketing company Major Pharmaceuticals and CVS Health (CVS) in Ohio. In Major's catalog is Omeprazole, a generic version of Prilosec, which is available without a subscription. CVS Caremark, which had majority share of pharmacy benefit management services in Ohio, didn't use Maximum Allowable Cost for the product, which led to the state of Ohio paying $6.74 per tablet, or 19 times the amount somebody without a subscription can buy it, Coldwell tells investors in a research note, citing his own investigation. Meanwhile, over the course of five quarters in Ohio, Major's volume market share went from less than 2% to nearly 60% while dollar market share went from 12% to 95%, adds the analyst. He asks, "How does this happen?" The state of Ohio, "like so many other buyers, feels like it is paying too much for drugs," concludes Coldwell.
03/04/19
BARD
03/04/19
NO CHANGE
Target $102
BARD
Outperform
Aetna lowering of screening age positive for Exact Sciences, says Baird
CVS Health (CVS) unit Aetna on Friday revised its policy to state that colorectal cancer screening is considered medically necessary for average-risk persons aged 45 years and older when recommended by their physician, Baird analyst Catherine Ramsey Schulte tells investors in a research note. Aetna's previous version covered for average-risk persons beginning at age 50 years, the analyst points out. While admitting further uptake in ages 45-49 will require medical education among doctors, Ramsey Schulte views Aetne'a update as "incrementally positive" for Exact Sciences. She keeps an Outperform rating on the shares with a $102 price target. The stock in early trading is up 1% to $93.57.
QCOM Qualcomm
$54.80

1.48 (2.78%)

03/04/19
SUSQ
03/04/19
NO CHANGE
SUSQ
Positive
Cirrus Logic, Qualcomm winners in S10 teardown, Knowles loser, says Susquehanna
Susquehanna analyst Christopher Rolland disassembled the Korean version of Samsung's (SSNLF) Galaxy S10 and he found Cirrus Logic (CRUS) won the new amplifier sockets as well as maintaining their codec in the Exynos version. The analyst found Qualcomm (QCOM) has won the under-glass fingerprint sensor, apparently for all designs, not just those using a Qualcomm AP. He said this is a new source of revenue for Qualcomm. He noted the big loser was Knowles (KN) because traditionally Samsung used microphone MEMS from Knowles but in the GS10 not one but two microphones are supplied by GoerTek.
01/31/19
MZHO
01/31/19
NO CHANGE
Target $62
MZHO
Buy
Qualcomm price target lowered to $62 from $66 at Mizuho
Mizuho analyst Vijay Rakesh lowered his price target for Qualcomm to $62 saying the company reported a slightly below consensus December quarter but guided to an in-line March quarter. Handsets remain in a slowdown, Rakesh tells investors in a research note. However, he keeps a Buy rating on Qualcomm as the company "awaits some critical litigations and the 2020 5G ramp."
01/31/19
BMOC
01/31/19
NO CHANGE
Target $54
BMOC
Market Perform
Qualcomm price target lowered to $54 from $60 at BMO Capital
BMO Capital analyst Tim Long lowered his price target on Qualcomm to $54 and kept his Market Perform rating after its mixed Q4 results, with the top-line miss driven by weaker chip and royalty revenues being offset by an earnings beat due to lower operating expense and a $150M Huawei payment. The analyst also sees growing uncertainty for the stock from the weak China smartphone market and heating up litigation activity.
02/26/19
STFL
02/26/19
NO CHANGE
Target $57
STFL
Hold
Qualcomm legal overhang limits upside despite 5G leadership, says Stifel
After Qualcomm's "barrage" of product announcements timed for Mobile World Congress this week, Stifel analyst Kevin Cassidy said he believes the company most notable announcements were its second generation 5G modem and second generation RF Front-End solutions. While he sees Qualcomm as the clear leader in 5G modem technology, Cassidy noted that significant 5G modem related revenue may be two years away and he believes the legal overhang of the recently concluded FTC trial limits Qualcomm's share price upside. Cassidy, who thinks Qualcomm shares could trade in a range of about $30 to $90 depending on the outcome of the legal disputes, keeps a Hold rating and $57 price target on the stock.
ROKU Roku
$71.91

3.11 (4.52%)

02/22/19
NEED
02/22/19
NO CHANGE
Target $65
NEED
Buy
Roku price target raised to $65 from $45 at Needham
Needham analyst Laura Martin raised her price target on Roku to $65 and kept her Buy rating after its beat-and-raise Q4 and FY19 guidance. The analyst notes that the company "over-delivered" on revenue thanks to the 21% sales increase in the Player segment, also generating positive EBITDA that grew 70% from last year. Martin further cites Roku's 60% increase in total streaming hours, 7.8M increase in active users, and its doubled rate of monetization of ad impressions made in 2018. The analyst also sees the opportunity in advertising for Roku, since the product is available in 10M homes without a linear TV bundle.
02/22/19
WEDB
02/22/19
DOWNGRADE
Target $55
WEDB
Neutral
Roku downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Michael Pachter downgraded Roku to Neutral from Outperform and cut his price target to $55 from $65 following the company's Q4 results. In a research note to investors, Pachter says Roku has built an "exceptional" platform and has positioned itself as best-in-class for OTT advertising, but lowered his long-term EPS estimate on lower operating margin assumption given a greater likelihood of higher spending levels than he previously modeled.
02/22/19
02/22/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kraft Heinz (KHC) downgraded to Equal Weight from Overweight at Barclays, to Hold from Buy at Berenberg and Stifel, and well as to Neutral from Buy at BofA/Merrill, UBS, Piper Jaffray, and JPMorgan. 2. Broadcom (AVGO) downgraded to Market Perform from Outperform at Cowen with analyst Matthew Ramsay saying he sees the shares as fairly valued at current levels. 3. Stamps.com (STMP) downgraded to Sell from Neutral at Roth Capital and to Hold from Buy at Maxim. 4. Nordstrom (JWN) downgraded to Hold from Buy at Deutsche Bank with analyst Paul Trussell saying while Nordstrom "continues to operate unique assets," he no longer anticipates an inflection in EBIT dollar growth near-term. 5. Roku (ROKU) downgraded to Neutral from Outperform at Wedbush with analyst Michael Pachter saying Roku has built an "exceptional" platform and has positioned itself as best-in-class for OTT advertising, but lowered his long-term EPS estimate on lower operating margin assumption given a greater likelihood of higher spending levels than he previously modeled. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/19
DADA
03/06/19
NO CHANGE
Target $80
DADA
Buy
Roku price target raised to $80 from $60 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on Roku to $80 and kept his Buy rating after reviewing its 10-K filing, citing his increased confidence in the company's near-term revenue growth and his increased EBITDA margin forecast of 35.0% vs. 27.5% prior. The analyst sees the Roku Channel as a "material driver of future growth" offering access to some 10K movies and TV shows while "becoming one of the leading sources of advertising inventory". Forte also believes that Roku's heavy investment in the platform will yield "material long-term platform revenue growth" and expects the company's R&D expense to be scaled back over time.
ACB Aurora Cannabis
$7.87

-0.22 (-2.72%)

03/05/19
COWN
03/05/19
INITIATION
COWN
Outperform
Cowen starts Aurora at Outperform, replaces Canopy as top pick
Cowen analyst Vivien Azer initiated coverage of Aurora Cannabis (ACB) with an Outperform rating and C$14 price target. Aurora is "uniquely positioned" to drive leadership in both market share and profitability with the Canadian adult use market in the "early innings," Azer tells investors in a research note. Her analysis pegs Aurora's market share at an "impressive" 20% to date and shows the company has the number two position by in-stock SKU. Azer designated Aurora Cannabis as her Top Pick in cannabis, replacing Canopy Growth (CGC). Given that Canopy currently trades at 18 times estimated fiscal 2030 revenue estimates, Aurora's trading multiple "is defensible," says the analyst.
03/05/19
COWN
03/05/19
INITIATION
COWN
Outperform
Aurora Cannabis initiated with an Outperform at Cowen
Cowen analyst Vivien Azer started Aurora Cannabis with an Outperform rating and C$14 price target.
03/04/19
MELI
03/04/19
INITIATION
MELI
Overweight
Aurora Cannabis initiated with an Overweight at Melius Research
Melius Research analyst Rob Wertheimer launched coverage of the cannabis space with a Neutral industry view and named Aurora Cannabis his top pick with an Overweight rating. Cannabis will be a multi hundred-billion-dollar market with time and continued legal progress, Wertheimer tells investors in a research note. However, he believes "lots of things have to happen to unlock potential." For Aurora, he sees upside from potential alliances, early scale in production and its global reach.
03/05/19
03/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) initiated with a Buy at Needham. 2. Lennox (LII) initiated with a Neutral at Goldman Sachs. 3. Aurora Cannabis (ACB) initiated with an Outperform at Cowen. 4. Floor & Decor (FND) initiated with an Outperform at Baird. 5. Gossamer Bio (GOSS) initiated with an Outperform at Evercore ISI and SVB Leerink, an Overweight at Barclays, and a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CAT Caterpillar
$134.80

-2.36 (-1.72%)

02/26/19
02/26/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Caterpillar (CAT) downgraded to Sell from Buy at UBS by analyst Steven Fisher, who believes believes ~55% of Caterpillar's end markets will peak in 2019, pressuring revenue and margins in 2020 as demand declines. Continued growth in mining and share buybacks will not be enough to offset headwinds in construction and oil and gas, he said. 2. Foot Locker (FL) downgraded to Hold from Buy at Pivotal Research by analyst Mitchel Kummetz, who sees a less favorable risk/reward into the company's Q4 results on March 1. The analyst expects "solid" Q4 results but believes the company's Q1 is likely off to a slow start. An easy two-year comparison may not be enough for Foot Locker to generate solid Q1 same-store-sales, as the quarter is likely off to a slow start on delayed/reduced tax refunds, he said. 3. Windstream (WIN) downgraded to Underperform from Market Perform at Wells Fargo by analyst Jennifer Fritzsche to reflect the company's filing for Chapter 11 restructuring and uncertainty surrounding the short to medium term operations and financing challenges. 4. Palo Alto Networks (PANW) downgraded to Market Perform from Outperform at Northland by analyst Robert Breza, who stated that he expects upside to Q2 revenue and EPS given the company's track record of earnings beats, but he also expects EPS to be guided down as the company invests for growth while absorbing the Demisto acquisition. 5. CenturyLink (CTL) downgraded to Neutral from Buy at BofA/Merrill by analyst David Barden, who said he learned that the dividend cut was based on leverage, maturities, and the state of the bond market, not any fundamental change in the business, revenue fixes are being taken but the top line will not inflect this year, and no structural changes are underway at this time. The analyst came away more confident about underlying trends, but believes investors are more focused on near-term revenue and believes Q1 consensus estimates are too high, setting up for poor stock performance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/04/19
BMOC
02/04/19
NO CHANGE
Target $160
BMOC
Outperform
Caterpillar price target lowered to $160 from $185 at BMO Capital
BMO Capital analyst Joel Tiss lowered his price target on Caterpillar to $160, citing the management's outlook for "modest" 2019 revenue growth reflecting either a closer alignment with the broader business cycle or a "healthy dose of conservatism in an uncertain environment". Longer term, the analyst keeps his Outperform rating on Caterpillar, noting that "more than half of company sales and profits are from end markets that are much less than halfway to assumed peak levels." Tiss further notes that the company's "significant cost reductions and other operating efficiencies will be strong enough to drive EPS meaningfully above expectations".
02/15/19
OTRG
02/15/19
NO CHANGE
OTRG
Mixed
Mining equipment market view downgraded to Mixed from Positive at OTR Global
OTR Global said its checks with mining industry executives in North America, Asia, EMEA and Latin America indicated that the mining equipment market had deteriorated to mixed currently from positive in November. Miners expect the rate of growth in new mining equipment budgets to moderate during 2019, citing global trade issues and commodity prices, the firm stated.
02/26/19
UBSW
02/26/19
DOWNGRADE
Target $125
UBSW
Sell
Caterpillar downgraded to Sell from Buy at UBS
UBS analyst Steven Fisher double downgraded Caterpillar to Sell from Buy and cut his price target for the shares to $125 from $154. The stock closed yesterday up $2.80 to $141.41. The analyst believes ~55% of Caterpillar's end markets will peak in 2019, pressuring revenue and margins in 2020 as demand declines. Continued growth in mining and share buybacks will not be enough to offset headwinds in construction and oil and gas, Fisher tells investors in a research note. He expects Caterpillar's earnings will decline 8% year-over-year in 2020 and believes this is not priced into the shares. Consensus earnings estimates, which imply 8% year-over-year earnings growth in 2020, are 16% too high, says Fisher. As such, he expects downward earnings revisions to pressure Caterpillar shares over the next 12 months.
TGT Target
$76.89

0.89 (1.17%)

03/06/19
DBAB
03/06/19
NO CHANGE
Target $84
DBAB
Buy
Target price target raised to $84 from $80 at Deutsche Bank
Deutsche Bank analyst Mike Baker raised his price target for Target to $84 citing the company's better than expected 2019 guidance. However, the analyst keeps a Hold rating on the shares following Target's analyst day. He sees the company as a "show-me" story with some headwinds that could keep pressure on margins.
03/06/19
FBCO
03/06/19
NO CHANGE
Target $85
FBCO
Outperform
Target price target raised to $85 from $79 at Credit Suisse
Credit Suisse analyst Seth Sigman raised his price target for Target to $85 from $79 following the company's analyst day. At the event, management provided a more optimistic earnings algorithm for 2019 and beyond, supported by continued market share gains, an improving merchandise mix, and cost savings across various buckets including digital fulfillment, the analyst notes. Sigman expects the message of margin improvement to be met with some skepticism, but Target's significant comps outperformance in Q4, combined with the profit inflection, should help instill some confidence. He reiterates an Outperform rating on the shares.
03/06/19
BMOC
03/06/19
NO CHANGE
Target $78
BMOC
Market Perform
Target price target raised to $78 from $70 at BMO Capital
BMO Capital analyst Kelly Bania raised her price target on Target (TGT) to $78, citing its "solid" same-store sales outlook and higher EBIT margin assumptions. The analyst is keeping her Market Perform rating on the shares however given the "unpredictability that sales mix can have on margins". As such, Bania is also maintaining her assumed 12- to 13- times forward earnings multiple in her Target model, which is lower than her multiple assumptions for discount store peers Walmart (WMT) and Costco (COST).
03/05/19
BARD
03/05/19
NO CHANGE
Target $90
BARD
Outperform
Target price target raised to $90 from $86 at Baird
Baird analyst Peter Benedict raised his price target on Target to $90 and kept his Outperform rating after its Q4 results and Investor Meeting presentation, anticipating "continued solid comps and an inflection in operating profit performance". The analyst calls Target his "top large-cap value idea" this year and believes that its perception of having "profitless growth" can change as the company delivers in the months ahead.
VMW VMware
$170.11

-2.58 (-1.49%)

03/06/19
03/06/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. TripAdvisor (TRIP) downgraded to Underperform from Market Perform at Cowen with analyst Kevin Kopelman citing a weak start to 2019, expectations for weaker usage, and worries about younger age demos using Google (GOOG). 2. Teva (TEVA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger citing his belief that the stock's premium valuation largely prices in expectations for upside in the coming quarters due to cost cutting and conservative Copaxone guidance. 3. VMware (VMW) downgraded to Sell from Neutral at Goldman Sachs, while Pivotal Software (PVTL) was downgraded to Neutral from Buy. 4. Ormat Technologies (ORA) downgraded to Neutral from Overweight at JPMorgan with the firm's analyst citing a lack of catalysts for share appreciation in 2019. 5. CSX (CSX) downgraded to Hold from Buy at Stifel with analyst Michael Baudendistel saying he no longer sees a solid reason why shares should outperform the market in the next twelve months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/19
GSCO
03/06/19
DOWNGRADE
Target $177
GSCO
Sell
VMware downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Heather Bellini downgraded VMware (VMW) to Sell from Neutral with an unchanged price target of $177. The stock closed yesterday up 37c to $172.69. The analyst this morning also downgraded Pivotal Software (PVTL) to Neutral from Buy. While VMware has done an excellent job diversifying its revenue base away from core virtualization, the benefit from the resurgence in on-premise spending is starting to face more normalized comps, Bellini tells investors in a research note. The analyst is optimistic on the company's revenue potential from partnerships with platforms such as Amazon Web Services (AMZN), but she believes the stock's current multiple is factoring in "material upside" to revenue and earnings estimates in 2019 and 2020.
03/04/19
MAXM
03/04/19
NO CHANGE
MAXM
Hold
VMware's AWS synergies likely priced in, says Maxim
Maxim analyst Nehal Chokshi kept his Hold rating on VMWare (VMW) and removed his $155 price target, saying the company's higher than expected license revenue was driven by the "overachievement" from its Dell (DELL) synergies. The analyst believes that VMWare's guidance also implies "slowing incremental Dell synergies and accelerating AWS (AMZN) synergies", which he sees as likely "priced in".
03/01/19
FBCO
03/01/19
NO CHANGE
Target $185
FBCO
Neutral
VMware price target raised to $185 from $160 at Credit Suisse
Credit Suisse analyst Brad Zelnick maintained a Neutral rating on VMware but raised his price target to $185 from $160 following the company's Q4 results. In a research note to investors, Zelnick says he is raising his FY20 revenue/EPS estimates to $10.03B/$6.49 from $9.92B/$6.69.
UXIN Uxin
$5.40

0.25 (4.85%)

12/21/18
GSCO
12/21/18
DOWNGRADE
Target $9.3
GSCO
Neutral
Uxin downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Ronald Keung downgraded Uxin to Neutral while raising his price target for the shares to $9.30 from $9.10. The analyst cites valuation for the downgrade following the recent rally in the shares.
01/15/19
JPMS
01/15/19
NO CHANGE
Target $7
JPMS
Overweight
JPMorgan reiterates call for 100% upside in Uxin shares
In a research note titled "A great start in 2019; Reiterate 100% upside," JPMorgan analyst Nick Lai says Uxin yesterday reported "very strong" December year-over-year transaction growth of 44%. Contrary to a "miserable new car market" in China, the used car market has performed well, up 13% last year and is expected to continue its double-digit growth rate in 2019 and 2020, Lai tells investors in a research note. He calls Uxin a leader in China's e-commerce used car market. The analyst still sees 100% upside potential in Uxin shares and keeps an Overweight rating on the name with a $7 price target.
01/10/19
JPMS
01/10/19
UPGRADE
Target $7
JPMS
Overweight
JPMorgan upgrades Uxin to Overweight with 100% potential upside
JPMorgan analyst Nick Lai upgraded Uxin to Overweight from Neutral while lowering his price target for the shares to $7 from $7.40. The stock closed yesterday up 34c to $3.55. The analyst sees 100% potential share upside amid continued growth in China's used car demand. Uxin has the largest used car e-commerce platform in China.
01/10/19
JPMS
01/10/19
UPGRADE
JPMS
Overweight
Uxin upgraded to Overweight from Neutral at JPMorgan

TODAY'S FREE FLY STORIES

21:25
03/25/19
03/25
21:25
03/25/19
21:25
General news
Fed's Rosengren warned that U.S. Q1 growth is likely to be weak »

Fed's Rosengren…

BBBY

Bed Bath & Beyond

$13.87

0.17 (1.24%)

20:44
03/25/19
03/25
20:44
03/25/19
20:44
Periodicals
Activist firms seek to replace Bed Bath & Beyond board, CEO, WSJ says »

Activist funds -Legion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

RTN

Raytheon

$180.58

-0.82 (-0.45%)

, BA

Boeing

$370.52

8.37 (2.31%)

20:36
03/25/19
03/25
20:36
03/25/19
20:36
Hot Stocks
Raytheon kill vehicle hits ICBM target in first dual-salvo test »

For the first time, the…

RTN

Raytheon

$180.58

-0.82 (-0.45%)

BA

Boeing

$370.52

8.37 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

20:35
03/25/19
03/25
20:35
03/25/19
20:35
General news
The "Summary of Opinions" from the BoJ's March meeting »

The "Summary of…

WHD

Cactus

$36.03

1.225 (3.52%)

20:27
03/25/19
03/25
20:27
03/25/19
20:27
Hot Stocks
Cactus VP of Operations sells 229K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$56.67

-0.065 (-0.11%)

, MKC

McCormick

$143.88

1.58 (1.11%)

20:25
03/25/19
03/25
20:25
03/25/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$56.67

-0.065 (-0.11%)

MKC

McCormick

$143.88

1.58 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

CRTO

Criteo

$21.99

-3.4 (-13.39%)

20:19
03/25/19
03/25
20:19
03/25/19
20:19
Downgrade
Criteo rating change at KeyBanc »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

20:02
03/25/19
03/25
20:02
03/25/19
20:02
Periodicals
Samsung sees weaker environment for display, memory in Q1, Bloomberg says »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$370.52

8.37 (2.31%)

19:51
03/25/19
03/25
19:51
03/25/19
19:51
Hot Stocks
U.S. MDA and Boeing Complete Historic Missile Defense Test »

The U.S. Missile Defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MCD

McDonald's

$185.66

-1.11 (-0.59%)

19:49
03/25/19
03/25
19:49
03/25/19
19:49
Periodicals
McDonald's purchase price of Dynamic Yield above $300M, Bloomberg says »

The purchase of Dynamic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

SSNLF

Samsung

$0.00

(0.00%)

19:32
03/25/19
03/25
19:32
03/25/19
19:32
Periodicals
Breaking Periodicals news story on Samsung »

Samsung sees Q1 below…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWR

American States Water

$71.51

0.505 (0.71%)

19:22
03/25/19
03/25
19:22
03/25/19
19:22
Hot Stocks
American States Water CEO sells 12.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$56.35

-1.38 (-2.39%)

19:10
03/25/19
03/25
19:10
03/25/19
19:10
Hot Stocks
Methanex confirms receipt of director nominees notice from M&G »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

, SAEX

SAExploration

$4.03

0.13 (3.33%)

18:55
03/25/19
03/25
18:55
03/25/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

DOWN AFTER EARNINGS:…

BECN

Beacon Roofing

$34.14

0.81 (2.43%)

SAEX

SAExploration

$4.03

0.13 (3.33%)

IQ

iQIYI

$24.01

-0.86 (-3.46%)

MYOK

MyoKardia

$51.87

-2.44 (-4.49%)

CTMX

CytomX Therapeutics

$10.76

0.33 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 21

    May

  • 27

    Mar

HPQ

HP Inc.

$18.97

-0.4 (-2.07%)

18:48
03/25/19
03/25
18:48
03/25/19
18:48
Periodicals
HP lawyer tells court Autonomy's Lynch inflated sales data, Reuters says »

A lawyer for HP told a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

PEGA

Pegasystems

$63.61

-0.27 (-0.42%)

18:45
03/25/19
03/25
18:45
03/25/19
18:45
Hot Stocks
Pegasystems CEO: We are massively changing our marketing strategy »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SMTC

Semtech

$52.59

-0.38 (-0.72%)

18:32
03/25/19
03/25
18:32
03/25/19
18:32
Hot Stocks
Semtech CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TMO

Thermo Fisher

$268.89

5.015 (1.90%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Hot Stocks
Thermo Fisher CEO: We have a very disciplined M&A process »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:24
03/25/19
03/25
18:24
03/25/19
18:24
Periodicals
Parliament forces votes on Brexit plan options, Bloomberg reports »

Lawmakers of U.K.…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.99

-0.56 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$185.66

-1.11 (-0.59%)

18:23
03/25/19
03/25
18:23
03/25/19
18:23
Hot Stocks
McDonald's to acquire Dynamic Yield, terms not stated »

McDonald's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 28

    May

BA

Boeing

$370.52

8.37 (2.31%)

18:22
03/25/19
03/25
18:22
03/25/19
18:22
Periodicals
Boeing software fix to prevent repeated activiation of MCAS, Reuters says »

A Boeing software repair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ACHC

Acadia

$29.47

-0.59 (-1.96%)

17:58
03/25/19
03/25
17:58
03/25/19
17:58
Hot Stocks
Acadia says President Brett Turner leaving by mutual agreement »

Brent Turner, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.78

-2.33 (-1.22%)

17:41
03/25/19
03/25
17:41
03/25/19
17:41
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

ZFGN

Zafgen

$2.70

-0.15 (-5.26%)

17:38
03/25/19
03/25
17:38
03/25/19
17:38
Hot Stocks
Armistice Capital reports 5.6% passive stake in Zafgen »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$268.56

0.27 (0.10%)

17:36
03/25/19
03/25
17:36
03/25/19
17:36
Hot Stocks
Northrop Grumman awarded $245.05M Navy contract modification »

Northrop Grumman has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.